Association of nuclear localization of SHP2 and YAP1 with unfavorable prognosis in non-small cell lung cancer
- 18 January 2019
- journal article
- research article
- Published by Elsevier BV in Pathology - Research and Practice
- Vol. 215 (4), 801-806
- https://doi.org/10.1016/j.prp.2019.01.027
Abstract
No abstract availableKeywords
Funding Information
- Chi Mei Medical Center, Tainan, Taiwan (CMFHR 10719)
This publication has 24 references indexed in Scilit:
- Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and METJournal of Hepatology, 2018
- Shp2 promotes liver cancer stem cell expansion by augmenting β‐catenin signaling and predicts chemotherapeutic response of patientsHepatology, 2016
- SHP2 phosphatase as a novel therapeutic target for melanoma treatmentOncotarget, 2016
- Functions of Shp2 in cancerJournal of Cellular and Molecular Medicine, 2015
- Shp2 promotes metastasis of prostate cancer by attenuating the PAR3/PAR6/aPKC polarity protein complex and enhancing epithelial-to-mesenchymal transitionOncogene, 2015
- Upregulation of Src homology phosphotyrosyl phosphatase 2 (Shp2) expression in oral cancer and knockdown of Shp2 expression inhibit tumor cell viability and invasion in vitroOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2014
- Expression of SHP2 and Related Markers in Non–Small Cell Lung CancerApplied Immunohistochemistry & Molecular Morphology, 2013
- YAP and TAZ, Hippo Signaling Targets, Act as a Rheostat for Nuclear SHP2 FunctionDevelopmental Cell, 2013
- Src homology phosphotyrosyl phosphatase‐2 expression is an independent negative prognostic factor in human breast cancerHistopathology, 2013
- Expression and Clinical Significance of SHP2 in Gastric CancerJournal of International Medical Research, 2012